Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL - Wikidata - awgldk - TriplyDB

Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL

Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL

http://www.wikidata.org/entity/Q24610164

about

Preventing Cryptococcosis-Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy Cryptococcus gattii infections Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda.Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.Serotype sensitivity of a lateral flow immunoassay for cryptococcal antigen New Insights into HIV/AIDS-Associated Cryptococcosis.Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia.Asymptomatic cryptococcemia in resource-limited settings.'Time-to-amphotericin B' in cryptococcal meningitis in a European low-prevalence setting: analysis of diagnostic delays.The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time.Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.Utility of Cryptococcal Antigen Screening and Evolution of Asymptomatic Cryptococcal Antigenemia among HIV-Infected Women Starting Antiretroviral Therapy in Thailand.Cryptococcosis.

P2860

Q26994750-E7B2D272-EE92-4C89-AA42-2DE6B2606791 Q27002687-9DEFED37-CE3F-4FB0-BE83-46D63F63D5C7 Q34516367-B60EF6A6-8ACC-4753-BB7B-B06F69E25E85 Q34692926-98852181-ACC6-48D6-B1D8-6B97B1614607 Q35171867-B5DF667B-0ACE-426C-BCBF-91B97F4DD82B Q36757799-4826E4AD-BF5D-4E23-B35D-EEA9659150A7 Q37156556-C17FFC03-F633-452C-B1D1-56CD8A625D0D Q37215923-07A1D182-80AD-4EA8-8419-4C59C0997CCD Q37259640-35B5D59B-E28D-4083-817A-0F6D8611AAFF Q38203799-0542935C-FA5C-4DCA-ADFA-441A3E71EE36 Q38328870-24B452EE-7518-48CC-BC1A-B67BACACFB5C Q39379643-22FF5A2B-560A-43C7-859B-FFB06A764449 Q42248892-D8D1AC50-F274-4F1E-842B-954AB13ACDCE Q51818572-7702F3A0-0E06-4A94-9603-DF3DB9A9EF2F

P2860

Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL

http://www.wikidata.org/entity/Q24610164

description

2012 nî lūn-bûn

@nan

2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Reconsidering cryptococcal ant ...... ersons with CD4 <100 cells/mcL

@ast

Reconsidering cryptococcal ant ...... ersons with CD4 <100 cells/mcL

@en

Reconsidering cryptococcal ant ...... ersons with CD4 <100 cells/mcL

@nl

type

label

Reconsidering cryptococcal ant ...... ersons with CD4 <100 cells/mcL

@ast

Reconsidering cryptococcal ant ...... ersons with CD4 <100 cells/mcL

@en

Reconsidering cryptococcal ant ...... ersons with CD4 <100 cells/mcL

@nl

prefLabel

Reconsidering cryptococcal ant ...... ersons with CD4 <100 cells/mcL

@ast

Reconsidering cryptococcal ant ...... ersons with CD4 <100 cells/mcL

@en

Reconsidering cryptococcal ant ...... ersons with CD4 <100 cells/mcL

@nl

P1433

Q24610164-86C2C025-5E7E-488F-A768-62EECDACEBD6

P1476

Q24610164-89C05930-2379-4889-8F74-AB250400CE2A

P2093

Q24610164-FE0DCF1A-6F82-487F-8288-810C52AAEAC1

P2860

Q24610164-186EC9FF-711E-4784-AD3D-909FC777FB03

Q24610164-5A7C977B-E305-4973-B38F-C748C45F0055

Q24610164-5DE14E04-1AA9-4411-B457-0E943AF0F8F7

Q24610164-610465A7-89D6-46AE-BC2B-A0FC9A47A7F7

Q24610164-B95CD1BE-E377-4F77-B418-791F4DDC6DF2

Q24610164-BECCF9E4-EE1B-4B55-8817-81C56A21B33E

Q24610164-D739CDAB-7976-4965-8654-A101C8AECB8B

Q24610164-FCD61565-E651-40DF-A4F6-8ED286CBD89D

P304

Q24610164-3E9AF9C8-4C49-4397-BD19-DAB2B3EAC0F5

P31

Q24610164-7FFCDD2F-70A0-4DB1-B70C-4E6A463089DF

P356

Q24610164-0D99E9AE-AB33-404F-BC13-9A998D44E2CE

P407

Q24610164-F74B1BAF-C619-4AEA-8021-5BA522B27186

P433

Q24610164-0A9EE12A-EE02-472E-8D75-80108EB5ACE4

P478

Q24610164-9C3C6918-5DDA-4319-967D-FAD0F16F8B5D

P50

Q24610164-82EF17B2-D8DB-46C6-B141-D9A445D097CA

P577

Q24610164-9B4B29F8-EECD-497A-8C54-51D75642DEF1

P5875

Q24610164-FE191DC8-10B4-41E8-A1DE-9C7A25860B7B

P698

Q24610164-BF586CBE-9818-4AED-A2CB-D8F7FDE0D0E1

P921

Q24610164-AC9F72E4-6049-4854-8277-486CFE71C122

P932

Q24610164-96B372DB-1FDB-4245-813E-C157BE000B65

P356

P1433

Clinical Infectious Diseases

P1476

Reconsidering cryptococcal ant ...... ersons with CD4 <100 cells/mcL

@en

P2093

Radha Rajasingham

http://www.w3.org/2001/XMLSchema#string

P2860

Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings

Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care

Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS

Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.

Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort.

Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.

Late HIV testing - 34 states, 1996-2005.

P304

1742-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIS725

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P50

David R. Boulware

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230733799

http://www.w3.org/2001/XMLSchema#string

P698

22918997

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

P932

3501329

http://www.w3.org/2001/XMLSchema#string